[{"id":"759667ed-3d93-4013-b60b-a6259ed986b1","acronym":"MCC-21113","url":"https://clinicaltrials.gov/study/NCT05316129","created_at":"2022-04-07T13:56:37.707Z","updated_at":"2025-02-25T15:12:44.059Z","phase":"Phase 1","brief_title":"Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer","source_id_and_acronym":"NCT05316129 - MCC-21113","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" PD-L1 • BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["PD-L1 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e liraltagene autoleucel (lira-cel)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 04/28/2022","start_date":" 04/28/2022","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2025-02-13"}]